At 32 weeks, the least squares mean ACQ-5 score changed by -1.45 (+/- 0.107) points and the SGRQ scores changed by -19.0 (+/- 1.64) points.
“But you also see that the improvement seems steady.”
At 4 weeks, 57% of patients experienced a minimum clinically important difference in ACQ-5 score and at 12 weeks, 69% of patients experienced a minimum clinically important difference in SGRQ response. At 32 weeks, minimum clinically important difference ACQ-5 and SGRQ scores were reported for 77% and 79% of patients, respectively.
Dr. Albers and his colleagues also analyzed how these results might look in a randomized phase 3 setting by comparing their results to previously reported data from the MENSA (mepolizumab treatment in patients with severe eosinophilic asthma) and epolizumab for severe eosinophilic asthma) DREAM studies. They reported that compared with the previously reported placebo cohorts, patients who switched to mepolizumab experienced an ACQ-5 score improvement of -0.90 (P less than 0.001).